Rux­oli­tinib pass­es an­oth­er PhI­II test for graft-ver­sus-host dis­ease, a win for In­cyte and No­var­tis

Rux­oli­tinib has proven it­self a stel­lar mon­ey­mak­er for In­cyte and No­var­tis, and it should come as no sur­prise that the drug’s ef­fi­ca­cy reached ex­pec­ta­tions in yet an­oth­er Phase III tri­al.

The two com­pa­nies an­nounced Thurs­day that rux­oli­tinib — sold as Jakafi by In­cyte in the US and as Jakavi by No­var­tis else­where — met its pri­ma­ry end­point in a study eval­u­at­ing treat­ment in pa­tients with chron­ic graft-ver­sus-host dis­ease who did not re­spond well to steroids. Mea­sured against the best avail­able ther­a­py, rux­oli­tinib showed a sig­nif­i­cant­ly im­proved over­all re­sponse rate af­ter 24 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER